{"pmid":32433272,"title":"Fecal Microbiota Transplantation for Recurrent Clostridioides difficile infection: The COVID-19 Era.","text":["Fecal Microbiota Transplantation for Recurrent Clostridioides difficile infection: The COVID-19 Era.","Am J Gastroenterol","Khanna, Sahil","Pardi, Darrell","32433272"],"journal":"Am J Gastroenterol","authors":["Khanna, Sahil","Pardi, Darrell"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32433272","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.14309/ajg.0000000000000689","topics":["Prevention"],"weight":1,"_version_":1667342288379969537,"score":9.490897,"similar":[{"pmid":32405509,"pmcid":"PMC7184446","title":"The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Current Understanding and Gap Analysis.","text":["The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Current Understanding and Gap Analysis.","The leading risk factor for Clostridioides (Clostridium) difficile infection (CDI) is broad-spectrum antibiotics, which lead to low microbial diversity, or dysbiosis. Current therapeutic strategies for CDI are insufficient, as they do not address the key role of the microbiome in preventing C. difficile spore germination into toxin-producing vegetative bacteria, which leads to symptomatic disease. Fecal microbiota transplant (FMT) appears to reduce the risk of recurrent CDI through microbiome restoration. However, a wide range of efficacy rates have been reported, and few placebo-controlled trials have been conducted, limiting our understanding of FMT efficacy and safety. We discuss the current knowledge gaps driven by questions around the quality and consistency of clinical trial results, patient selection, diagnostic methodologies, use of suppressive antibiotic therapy, and methods for adverse event reporting. We provide specific recommendations for future trial designs of FMT to provide improved quality of the clinical evidence to better inform treatment guidelines.","Open Forum Infect Dis","Wilcox, Mark H","McGovern, Barbara H","Hecht, Gail A","32405509"],"abstract":["The leading risk factor for Clostridioides (Clostridium) difficile infection (CDI) is broad-spectrum antibiotics, which lead to low microbial diversity, or dysbiosis. Current therapeutic strategies for CDI are insufficient, as they do not address the key role of the microbiome in preventing C. difficile spore germination into toxin-producing vegetative bacteria, which leads to symptomatic disease. Fecal microbiota transplant (FMT) appears to reduce the risk of recurrent CDI through microbiome restoration. However, a wide range of efficacy rates have been reported, and few placebo-controlled trials have been conducted, limiting our understanding of FMT efficacy and safety. We discuss the current knowledge gaps driven by questions around the quality and consistency of clinical trial results, patient selection, diagnostic methodologies, use of suppressive antibiotic therapy, and methods for adverse event reporting. We provide specific recommendations for future trial designs of FMT to provide improved quality of the clinical evidence to better inform treatment guidelines."],"journal":"Open Forum Infect Dis","authors":["Wilcox, Mark H","McGovern, Barbara H","Hecht, Gail A"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405509","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1093/ofid/ofaa114","keywords":["clostridioides difficile infection","sars-cov-2","shiga toxin-producing escherichia coli","fecal microbiota transplant","microbiome"],"topics":["Prevention"],"weight":1,"_version_":1666802845649731586,"score":133.78018},{"pmid":32326509,"title":"From Donor to Patient: Collection, Preparation and Cryopreservation of Fecal Samples for Fecal Microbiota Transplantation.","text":["From Donor to Patient: Collection, Preparation and Cryopreservation of Fecal Samples for Fecal Microbiota Transplantation.","Fecal Microbiota Transplantation (FMT) is suggested as an efficacious therapeutic strategy for restoring intestinal microbial balance, and thus for treating disease associated with alteration of gut microbiota. FMT consists of the administration of fresh or frozen fecal microorganisms from a healthy donor into the intestinal tract of diseased patients. At this time, in according to healthcare authorities, FMT is mainly used to treat recurrent Clostridium difficile. Despite the existence of a few existing stool banks worldwide and many studies of the FMT, there is no standard method for producing material for FMT, and there are a multitude of factors that can vary between the institutions. The main constraints for the therapeutic uses of FMT are safety concerns and acceptability. Technical and logistical issues arise when establishing such a non-standardized treatment into clinical practice with safety and proper governance. In this context, our manuscript describes a process of donor safety screening for FMT compiling clinical and biological examinations, questionnaires and interviews of donors. The potential risk of transmission of SARS-CoV-2 virus by the use of fecal microbiota for transplantation must be taken urgently into consideration. We discuss a standardized procedure of collection, preparation and cryopreservation of fecal samples through to the administration of material to patients, and explore the risks and limits of this method of FMT. The future success of medicine employing microbiota transplantation will be tightly related to its modulation and manipulation to combat dysbiosis. To achieve this goal, standard and strict methods need to be established before performing any type of FMT.","Diseases","Nicco, Carole","Paule, Armelle","Konturek, Peter","Edeas, Marvin","32326509"],"abstract":["Fecal Microbiota Transplantation (FMT) is suggested as an efficacious therapeutic strategy for restoring intestinal microbial balance, and thus for treating disease associated with alteration of gut microbiota. FMT consists of the administration of fresh or frozen fecal microorganisms from a healthy donor into the intestinal tract of diseased patients. At this time, in according to healthcare authorities, FMT is mainly used to treat recurrent Clostridium difficile. Despite the existence of a few existing stool banks worldwide and many studies of the FMT, there is no standard method for producing material for FMT, and there are a multitude of factors that can vary between the institutions. The main constraints for the therapeutic uses of FMT are safety concerns and acceptability. Technical and logistical issues arise when establishing such a non-standardized treatment into clinical practice with safety and proper governance. In this context, our manuscript describes a process of donor safety screening for FMT compiling clinical and biological examinations, questionnaires and interviews of donors. The potential risk of transmission of SARS-CoV-2 virus by the use of fecal microbiota for transplantation must be taken urgently into consideration. We discuss a standardized procedure of collection, preparation and cryopreservation of fecal samples through to the administration of material to patients, and explore the risks and limits of this method of FMT. The future success of medicine employing microbiota transplantation will be tightly related to its modulation and manipulation to combat dysbiosis. To achieve this goal, standard and strict methods need to be established before performing any type of FMT."],"journal":"Diseases","authors":["Nicco, Carole","Paule, Armelle","Konturek, Peter","Edeas, Marvin"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32326509","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.3390/diseases8020009","keywords":["covid-19","fmt","cryoconservation","fecal microbiota transplantation","fecal samples","gut microbiota","stool banks"],"topics":["Prevention"],"weight":1,"_version_":1666138494753308672,"score":84.686584},{"pmid":32425230,"pmcid":"PMC7233220","title":"The utility of fecal calprotectin in the era of COVID-19 pandemic.","text":["The utility of fecal calprotectin in the era of COVID-19 pandemic.","Gastroenterology","32425230"],"journal":"Gastroenterology","date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425230","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1053/j.gastro.2020.05.045","topics":["Prevention"],"weight":1,"_version_":1667352728824709120,"score":47.44957},{"pmid":32192627,"pmcid":"PMC7104244","title":"Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel.","text":["Screening of faecal microbiota transplant donors during the COVID-19 outbreak: suggestions for urgent updates from an international expert panel.","Lancet Gastroenterol Hepatol","Ianiro, Gianluca","Mullish, Benjamin H","Kelly, Colleen R","Sokol, Harry","Kassam, Zain","Ng, Siew","Fischer, Monika","Allegretti, Jessica R","Masucci, Luca","Zhang, Faming","Keller, Josbert","Sanguinetti, Maurizio","Costello, Samuel P","Tilg, Herbert","Gasbarrini, Antonio","Cammarota, Giovanni","32192627"],"journal":"Lancet Gastroenterol Hepatol","authors":["Ianiro, Gianluca","Mullish, Benjamin H","Kelly, Colleen R","Sokol, Harry","Kassam, Zain","Ng, Siew","Fischer, Monika","Allegretti, Jessica R","Masucci, Luca","Zhang, Faming","Keller, Josbert","Sanguinetti, Maurizio","Costello, Samuel P","Tilg, Herbert","Gasbarrini, Antonio","Cammarota, Giovanni"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32192627","source":"PubMed","week":"202012|Mar 16 - Mar 22","doi":"10.1016/S2468-1253(20)30082-0","topics":["Prevention"],"weight":1,"_version_":1666138490054639617,"score":41.99298},{"pmid":32441243,"title":"Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March-April 2020.","text":["Clostridiodes difficile in COVID-19 Patients, Detroit, Michigan, USA, March-April 2020.","We describe 9 patients at a medical center in Detroit, Michigan, USA, with severe acute respiratory syndrome coronavirus 2 and Clostridiodes difficile. Both infections can manifest as digestive symptoms and merit screening when assessing patients with diarrhea during the coronavirus disease pandemic. These co-infections also highlight the continued importance of antimicrobial stewardship.","Emerg Infect Dis","Sandhu, Avnish","Tillotson, Glenn","Polistico, Jordan","Salimnia, Hossein","Cranis, Mara","Moshos, Judy","Cullen, Lori","Jabbo, Lavina","Diebel, Lawrence","Chopra, Teena","32441243"],"abstract":["We describe 9 patients at a medical center in Detroit, Michigan, USA, with severe acute respiratory syndrome coronavirus 2 and Clostridiodes difficile. Both infections can manifest as digestive symptoms and merit screening when assessing patients with diarrhea during the coronavirus disease pandemic. These co-infections also highlight the continued importance of antimicrobial stewardship."],"journal":"Emerg Infect Dis","authors":["Sandhu, Avnish","Tillotson, Glenn","Polistico, Jordan","Salimnia, Hossein","Cranis, Mara","Moshos, Judy","Cullen, Lori","Jabbo, Lavina","Diebel, Lawrence","Chopra, Teena"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32441243","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3201/eid2609.202126","keywords":["covid-19","clostridiodes difficile","detroit","michigan","sars-cov-2","united states","antibiotics","antimicrobial drug resistance","bacteria","bacterial infections","co-infection","coronavirus disease","diarrhea","nosocomial infections","respiratory infections","severe acute respiratory syndrome coronavirus 2","viruses","zoonoses"],"locations":["Detroit","Michigan","USA","Clostridiodes","Detroit","Michigan","USA"],"countries":["United States"],"countries_codes":["USA|United States"],"topics":["Diagnosis"],"weight":1,"_version_":1667535119499395074,"score":40.672318}]}